Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   

COVID-19: Daily Top 10 Papers

  Neoplasms of the CNS

  Free Subscription

Articles published in Eur J Cancer

Retrieve available abstracts of 81 articles:
HTML format

Single Articles

    April 2021
  1. DIMITRIOU F, Zaremba A, Allayous C, Kahler KC, et al
    Sustainable responses in metastatic melanoma patients with and without brain metastases after elective discontinuation of anti-PD1-based immunotherapy due to complete response.
    Eur J Cancer. 2021;149:37-48.
    PubMed     Abstract available

  2. KARSCHNIA P, Vogelbaum MA, van den Bent M, Cahill DP, et al
    Evidence-based recommendations on categories for extent of resection in diffuse glioma.
    Eur J Cancer. 2021;149:23-33.
    PubMed     Abstract available

    March 2021
  3. PARTANEN M, Anghelescu DL, Hall L, Schreiber JE, et al
    Longitudinal associations between exposure to anesthesia and neurocognitive functioning in pediatric medulloblastoma.
    Eur J Cancer. 2021;148:103-111.
    PubMed     Abstract available

    February 2021
  4. GRAMATZKI D, Felsberg J, Hentschel B, Wolter M, et al
    Telomerase reverse transcriptase promoter mutation- and O(6)-methylguanine DNA methyltransferase promoter methylation-mediated sensitivity to temozolomide in isocitrate dehydrogenase-wild-type glioblastoma: is there a link?
    Eur J Cancer. 2021;147:84-94.
    PubMed     Abstract available

  5. CLEMENT PMJ, Dirven L, Eoli M, Sepulveda-Sanchez JM, et al
    Impact of depatuxizumab mafodotin on health-related quality of life and neurological functioning in the phase II EORTC 1410/INTELLANCE 2 trial for EGFR-amplified recurrent glioblastoma.
    Eur J Cancer. 2021;147:1-12.
    PubMed     Abstract available

    January 2021
  6. TOSONI A, Gatto L, Franceschi E, Di Nunno V, et al
    Association between socioeconomic status and survival in glioblastoma: An Italian single-centre prospective observational study.
    Eur J Cancer. 2021;145:171-178.
    PubMed     Abstract available

    December 2020
  7. CARAMANNA I, Bottomley A, Drijver AJ, Twisk J, et al
    Objective neurocognitive functioning and neurocognitive complaints in patients with high-grade glioma: Evidence of cognitive awareness from the European Organisation for Research and Treatment of Cancer brain tumour clinical trials.
    Eur J Cancer. 2020;144:162-168.
    PubMed     Abstract available

    November 2020
  8. HONG AM, Waldstein C, Shivalingam B, Carlino MS, et al
    Management of melanoma brain metastases: Evidence-based clinical practice guidelines by Cancer Council Australia.
    Eur J Cancer. 2020;142:10-17.
    PubMed     Abstract available

    October 2020
  9. RAUSCHENBACH L, Wieland A, Reinartz R, Kebir S, et al
    Drug repositioning of antiretroviral ritonavir for combinatorial therapy in glioblastoma.
    Eur J Cancer. 2020;140:130-139.
    PubMed     Abstract available

    September 2020
  10. MORENO L, Barone G, DuBois SG, Molenaar J, et al
    Accelerating drug development for neuroblastoma: Summary of the Second Neuroblastoma Drug Development Strategy forum from Innovative Therapies for Children with Cancer and International Society of Paediatric Oncology Europe Neuroblastoma.
    Eur J Cancer. 2020;136:52-68.
    PubMed     Abstract available

    July 2020
  11. FRANCESCHI E, Tosoni A, Bartolini S, Minichillo S, et al
    Histopathological grading affects survival in patients with IDH-mutant grade II and grade III diffuse gliomas.
    Eur J Cancer. 2020;137:10-17.
    PubMed     Abstract available

  12. CALLEC L, Lardy-Cleaud A, Guerrini-Rousseau L, Alapetite C, et al
    Relapsing intracranial germ cell tumours warrant retreatment.
    Eur J Cancer. 2020;136:186-194.
    PubMed     Abstract available

    June 2020
  13. BERGHOFF AS, Wippel C, Starzer AM, Ballarini N, et al
    Hypothyroidism correlates with favourable survival prognosis in patients with brain metastatic cancer.
    Eur J Cancer. 2020;135:150-158.
    PubMed     Abstract available

  14. CARRON R, Gaudy-Marqueste C, Amatore F, Padovani L, et al
    Stereotactic radiosurgery combined with anti-PD1 for the management of melanoma brain metastases: A retrospective study of safety and efficacy.
    Eur J Cancer. 2020;135:52-61.
    PubMed     Abstract available

    May 2020
  15. WOLPERT F, Berghoff AS, Grossenbacher B, Lareida A, et al
    Venous thromboembolic events in patients with brain metastases: the PICOS score.
    Eur J Cancer. 2020;134:75-85.
    PubMed     Abstract available

  16. PAGE S, Milner-Watts C, Perna M, Janzic U, et al
    Systemic treatment of brain metastases in non-small cell lung cancer.
    Eur J Cancer. 2020;132:187-198.
    PubMed     Abstract available

    April 2020
  17. TSAKONAS G, Lewensohn R, Botling J, Ortiz-Villalon C, et al
    An immune gene expression signature distinguishes central nervous system metastases from primary tumours in non-small-cell lung cancer.
    Eur J Cancer. 2020;132:24-34.
    PubMed     Abstract available

    March 2020
  18. CREED JH, Smith-Warner SA, Gerke TA, Egan KM, et al
    A prospective study of coffee and tea consumption and the risk of glioma in the UK Biobank.
    Eur J Cancer. 2020;129:123-131.
    PubMed     Abstract available

  19. DELUCHE E, Antoine A, Bachelot T, Lardy-Cleaud A, et al
    Contemporary outcomes of metastatic breast cancer among 22,000 women from the multicentre ESME cohort 2008-2016.
    Eur J Cancer. 2020;129:60-70.
    PubMed     Abstract available

    January 2020
  20. ACKER G, Zollfrank J, Jelgersma C, Nieminen-Kelha M, et al
    The CXCR2/CXCL2 signalling pathway - An alternative therapeutic approach in high-grade glioma.
    Eur J Cancer. 2020;126:106-115.
    PubMed     Abstract available

    December 2019
  21. PASQUIER D, Darlix A, Louvel G, Fraisse J, et al
    Treatment and outcomes in patients with central nervous system metastases from breast cancer in the real-life ESME MBC cohort.
    Eur J Cancer. 2019;125:22-30.
    PubMed     Abstract available

    October 2019
  22. GROSSI F, Genova C, Crino L, Delmonte A, et al
    Real-life results from the overall population and key subgroups within the Italian cohort of nivolumab expanded access program in non-squamous non-small cell lung cancer.
    Eur J Cancer. 2019;123:72-80.
    PubMed     Abstract available

  23. HENDRIKS LEL, Dooms C, Berghmans T, Novello S, et al
    Defining oligometastatic non-small cell lung cancer: A simulated multidisciplinary expert opinion.
    Eur J Cancer. 2019;123:28-35.
    PubMed     Abstract available

    September 2019
  24. JIANG T, Zhang Y, Li X, Zhao C, et al
    EGFR-TKIs plus bevacizumab demonstrated survival benefit than EGFR-TKIs alone in patients with EGFR-mutant NSCLC and multiple brain metastases.
    Eur J Cancer. 2019;121:98-108.
    PubMed     Abstract available

  25. LLUCH A, Gonzalez-Angulo AM, Casadevall D, Eterovic AK, et al
    Dynamic clonal remodelling in breast cancer metastases is associated with subtype conversion.
    Eur J Cancer. 2019;120:54-64.
    PubMed     Abstract available

    August 2019
  26. CHANG LC, Lim CK, Chang LY, Chen KY, et al
    Non-small cell lung cancer harbouring non-resistant uncommon EGFR mutations: Mutation patterns, effectiveness of epidermal growth factor receptor-tyrosine kinase inhibitors and prognostic factors.
    Eur J Cancer. 2019;119:77-86.
    PubMed     Abstract available

    June 2019
  27. COOMANS M, Dirven L, K Aaronson N, Baumert BG, et al
    The added value of health-related quality of life as a prognostic indicator of overall survival and progression-free survival in glioma patients: a meta-analysis based on individual patient data from randomised controlled trials.
    Eur J Cancer. 2019;116:190-198.
    PubMed     Abstract available

  28. HENDRIKS LEL, Bootsma G, Mourlanette J, Henon C, et al
    Survival of patients with non-small cell lung cancer having leptomeningeal metastases treated with immune checkpoint inhibitors.
    Eur J Cancer. 2019;116:182-189.
    PubMed     Abstract available

    May 2019
  29. SCHOENMAEKERS J, Hofman P, Bootsma G, Westenend M, et al
    Screening for brain metastases in patients with stage III non-small-cell lung cancer, magnetic resonance imaging or computed tomography? A prospective study.
    Eur J Cancer. 2019;115:88-96.
    PubMed     Abstract available

  30. SMITS M, Bendszus M, Collette S, Postma LA, et al
    Repeatability and reproducibility of relative cerebral blood volume measurement of recurrent glioma in a multicentre trial setting.
    Eur J Cancer. 2019;114:89-96.
    PubMed     Abstract available

    April 2019
  31. DE ROJAS T, Clementel E, Giralt J, Cruz O, et al
    Radiotherapy practice for paediatric brain tumours across Europe and quality assurance initiatives: Current situation, international survey and future perspectives.
    Eur J Cancer. 2019;114:36-46.
    PubMed     Abstract available

  32. PFAFF E, El Damaty A, Balasubramanian GP, Blattner-Johnson M, et al
    Brainstem biopsy in pediatric diffuse intrinsic pontine glioma in the era of precision medicine: the INFORM study experience.
    Eur J Cancer. 2019;114:27-35.
    PubMed     Abstract available

  33. HARRISON RA, Anderson MD, Cachia D, Kamiya-Matsuoka C, et al
    Clinical trial participation of patients with glioblastoma at The University of Texas MD Anderson Cancer Center.
    Eur J Cancer. 2019;112:83-93.
    PubMed     Abstract available

    March 2019
  34. PAULINE T, Clara A, Bastien O, Stephane D, et al
    Impact of radiotherapy administered simultaneously with systemic treatment in patients with melanoma brain metastases within MelBase, a French multicentric prospective cohort.
    Eur J Cancer. 2019;112:38-46.
    PubMed     Abstract available

    February 2019
  35. RAUSCHENBERG R, Bruns J, Brutting J, Daubner D, et al
    Impact of radiation, systemic therapy and treatment sequencing on survival of patients with melanoma brain metastases.
    Eur J Cancer. 2019;110:11-20.
    PubMed     Abstract available

  36. URSU R, Thomas L, Psimaras D, Chinot O, et al
    Angiotensin II receptor blockers, steroids and radiotherapy in glioblastoma-a randomised multicentre trial (ASTER trial). An ANOCEF study.
    Eur J Cancer. 2019;109:129-136.
    PubMed     Abstract available

  37. SHINJO D, Matsumoto K, Terashima K, Takimoto T, et al
    Volume effect in paediatric brain tumour resection surgery: analysis of data from the Japanese national inpatient database.
    Eur J Cancer. 2019;109:111-119.
    PubMed     Abstract available

    January 2019
  38. MONTEMURRO F, Ellis P, Anton A, Wuerstlein R, et al
    Safety of trastuzumab emtansine (T-DM1) in patients with HER2-positive advanced breast cancer: Primary results from the KAMILLA study cohort 1.
    Eur J Cancer. 2019;109:92-102.
    PubMed     Abstract available

    December 2018
  39. SUCHORSKA B, Schuller U, Biczok A, Lenski M, et al
    Contrast enhancement is a prognostic factor in IDH1/2 mutant, but not in wild-type WHO grade II/III glioma as confirmed by machine learning.
    Eur J Cancer. 2018;107:15-27.
    PubMed     Abstract available

    August 2018
  40. WITZEL I, Laakmann E, Weide R, Neunhoffer T, et al
    Treatment and outcomes of patients in the Brain Metastases in Breast Cancer Network Registry.
    Eur J Cancer. 2018;102:1-9.
    PubMed     Abstract available

    July 2018
  41. LE RHUN E, Genbrugge E, Stupp R, Chinot OL, et al
    Associations of anticoagulant use with outcome in newly diagnosed glioblastoma.
    Eur J Cancer. 2018;101:95-104.
    PubMed     Abstract available

  42. HABETS EJJ, Taphoorn MJB, Klein M, Vissers T, et al
    The level of reporting of neurocognitive outcomes in randomised controlled trials of brain tumour patients: A systematic review.
    Eur J Cancer. 2018;100:104-125.
    PubMed     Abstract available

    June 2018
  43. MILSCH L, Gesierich A, Kreft S, Livingstone E, et al
    Patterns of disease control and survival in patients with melanoma brain metastases undergoing immune-checkpoint blockade.
    Eur J Cancer. 2018;99:58-65.
    PubMed     Abstract available

  44. WELLER M
    Next generation neuro-oncology.
    Eur J Cancer. 2018;96:1-5.
    PubMed     Abstract available

    May 2018
  45. BONNEAU C, Paintaud G, Tredan O, Dubot C, et al
    Phase I feasibility study for intrathecal administration of trastuzumab in patients with HER2 positive breast carcinomatous meningitis.
    Eur J Cancer. 2018;95:75-84.
    PubMed     Abstract available

    April 2018
  46. WOLPERT F, Weller M, Berghoff AS, Rushing E, et al
    Diagnostic value of (18)F-fluordesoxyglucose positron emission tomography for patients with brain metastasis from unknown primary site.
    Eur J Cancer. 2018;96:64-72.
    PubMed     Abstract available

  47. EL-GALALY TC, Cheah CY, Bendtsen MD, Nowakowski GS, et al
    Treatment strategies, outcomes and prognostic factors in 291 patients with secondary CNS involvement by diffuse large B-cell lymphoma.
    Eur J Cancer. 2018;93:57-68.
    PubMed     Abstract available

    March 2018
  48. ALIFRANGIS C, Wilson P, Shamash J
    Letter to the Editor: Central nervous system relapse rate and dose intensification in poor risk metastatic germ cell tumours-A comment on: 'Patterns of relapse in poor prognosis germ cell tumours in the GETUG-13 trial: Implications for the assessment
    Eur J Cancer. 2018 Mar 31. pii: S0959-8049(18)30226.

  49. GAO Y, Weenink B, van den Bent MJ, Erdem-Eraslan L, et al
    Expression-based intrinsic glioma subtypes are prognostic in low-grade gliomas of the EORTC22033-26033 clinical trial.
    Eur J Cancer. 2018;94:168-178.
    PubMed     Abstract available

    February 2018
  50. LEVY A, Faivre-Finn C, Hasan B, De Maio E, et al
    Diversity of brain metastases screening and management in non-small cell lung cancer in Europe: Results of the European Organisation for Research and Treatment of Cancer Lung Cancer Group survey.
    Eur J Cancer. 2018;93:37-46.
    PubMed     Abstract available

    December 2017
  51. GNEKOW AK, Walker DA, Kandels D, Picton S, et al
    Corrigendum to "A European randomised controlled trial of the addition of etoposide to standard vincristine and carboplatin induction as part of an 18-month treatment programme for childhood (</=16 years) low grade glioma - A final report" [Eur J o
    Eur J Cancer. 2017 Dec 13. pii: S0959-8049(17)31415.

    November 2017
  52. LE RHUN E, Gorlia T
    Farewell to monomodality treatment in patients with WHO lower grade glioma?
    Eur J Cancer. 2017 Nov 24. pii: S0959-8049(17)31359.

  53. LORIOT Y, Pagliaro L, Flechon A, Mardiak J, et al
    Patterns of relapse in poor-prognosis germ-cell tumours in the GETUG 13 trial: Implications for assessment of brain metastases.
    Eur J Cancer. 2017;87:140-146.
    PubMed     Abstract available

  54. LE RHUN E, Bertrand N, Dumont A, Tresch E, et al
    Identification of single nucleotide polymorphisms of the PI3K-AKT-mTOR pathway as a risk factor of central nervous system metastasis in metastatic breast cancer.
    Eur J Cancer. 2017 Nov 2. pii: S0959-8049(17)31346.
    PubMed     Abstract available

  55. GEORGAKIS MK, Panagopoulou P, Papathoma P, Tragiannidis A, et al
    Central nervous system tumours among adolescents and young adults (15-39 years) in Southern and Eastern Europe: Registration improvements reveal higher incidence rates compared to the US.
    Eur J Cancer. 2017;86:46-58.
    PubMed     Abstract available

    September 2017
  56. GATTA G, Peris-Bonet R, Visser O, Stiller C, et al
    Geographical variability in survival of European children with central nervous system tumours.
    Eur J Cancer. 2017;82:137-148.
    PubMed     Abstract available

    August 2017
  57. PETRELLI F, Ghidini M, Lonati V, Tomasello G, et al
    The efficacy of lapatinib and capecitabine in HER-2 positive breast cancer with brain metastases: A systematic review and pooled analysis.
    Eur J Cancer. 2017;84:141-148.
    PubMed     Abstract available

  58. GAUDY-MARQUESTE C, Dussouil AS, Carron R, Troin L, et al
    Survival of melanoma patients treated with targeted therapy and immunotherapy after systematic upfront control of brain metastases by radiosurgery.
    Eur J Cancer. 2017;84:44-54.
    PubMed     Abstract available

    July 2017
  59. JIANG S, Eberhart CG, Zhang Y, Heo HY, et al
    Amide proton transfer-weighted magnetic resonance image-guided stereotactic biopsy in patients with newly diagnosed gliomas.
    Eur J Cancer. 2017;83:9-18.
    PubMed     Abstract available

  60. BLANK CU, Larkin J, Arance AM, Hauschild A, et al
    Open-label, multicentre safety study of vemurafenib in 3219 patients with BRAFV600 mutation-positive metastatic melanoma: 2-year follow-up data and long-term responders' analysis.
    Eur J Cancer. 2017;79:176-184.
    PubMed     Abstract available

    June 2017
  61. GNEKOW AK, Walker DA, Kandels D, Picton S, et al
    A European randomised controlled trial of the addition of etoposide to standard vincristine and carboplatin induction as part of an 18-month treatment programme for childhood (</=16 years) low grade glioma - A final report.
    Eur J Cancer. 2017;81:206-225.
    PubMed     Abstract available

  62. GANDHI L, Ignatius Ou SH, Shaw AT, Barlesi F, et al
    Efficacy of alectinib in central nervous system metastases in crizotinib-resistant ALK-positive non-small-cell lung cancer: Comparison of RECIST 1.1 and RANO-HGG criteria.
    Eur J Cancer. 2017;82:27-33.
    PubMed     Abstract available

  63. KARREMANN M, Kramer N, Hoffmann M, Wiese M, et al
    Haematological malignancies following temozolomide treatment for paediatric high-grade glioma.
    Eur J Cancer. 2017;81:1-8.
    PubMed     Abstract available

  64. DEVIC P, Amini-Adle M, Camdessanche JP, Dalle S, et al
    Demyelinating polyradiculoneuropathy under combined BRAF/MEK inhibitors.
    Eur J Cancer. 2017;78:103-104.

    May 2017
  65. PISCIONE PJ, Bouffet E, Timmons B, Courneya KS, et al
    Exercise training improves physical function and fitness in long-term paediatric brain tumour survivors treated with cranial irradiation.
    Eur J Cancer. 2017;80:63-72.
    PubMed     Abstract available

  66. STACCHIOTTI S, Saponara M, Frapolli R, Tortoreto M, et al
    Patient-derived solitary fibrous tumour xenografts predict high sensitivity to doxorubicin/dacarbazine combination confirmed in the clinic and highlight the potential effectiveness of trabectedin or eribulin against this tumour.
    Eur J Cancer. 2017;76:84-92.
    PubMed     Abstract available

    April 2017
  67. EL-GALALY TC, Villa D, Michaelsen TY, Hutchings M, et al
    The number of extranodal sites assessed by PET/CT scan is a powerful predictor of CNS relapse for patients with diffuse large B-cell lymphoma: An international multicenter study of 1532 patients treated with chemoimmunotherapy.
    Eur J Cancer. 2017;75:195-203.
    PubMed     Abstract available

  68. GEORGAKIS MK, Kalogirou EI, Liaskas A, Karalexi MA, et al
    Anthropometrics at birth and risk of a primary central nervous system tumour: A systematic review and meta-analysis.
    Eur J Cancer. 2017;75:117-131.
    PubMed     Abstract available

  69. SCHALK E, Zeremski V, Fischer T
    Impact of lymphopenia on prognosis of patients with primary central nervous system lymphoma.
    Eur J Cancer. 2017;75:280-283.

    March 2017
  70. TWELVES C, Cortes J, O'Shaughnessy J, Awada A, et al
    Health-related quality of life in patients with locally recurrent or metastatic breast cancer treated with etirinotecan pegol versus treatment of physician's choice: Results from the randomised phase III BEACON trial.
    Eur J Cancer. 2017;76:205-215.
    PubMed     Abstract available

  71. LEONE JP, Leone J, Zwenger AO, Iturbe J, et al
    Prognostic factors and survival according to tumour subtype in women presenting with breast cancer brain metastases at initial diagnosis.
    Eur J Cancer. 2017;74:17-25.
    PubMed     Abstract available

  72. DONIA M, Kimper-Karl ML, Hoyer KL, Bastholt L, et al
    The majority of patients with metastatic melanoma are not represented in pivotal phase III immunotherapy trials.
    Eur J Cancer. 2017;74:89-95.
    PubMed     Abstract available

    February 2017
  73. CHOONG ES, Lo S, Drummond M, Fogarty GB, et al
    Survival of patients with melanoma brain metastasis treated with stereotactic radiosurgery and active systemic drug therapies.
    Eur J Cancer. 2017;75:169-178.
    PubMed     Abstract available

  74. JANSSENS GO, Gandola L, Bolle S, Mandeville H, et al
    Survival benefit for patients with diffuse intrinsic pontine glioma (DIPG) undergoing re-irradiation at first progression: A matched-cohort analysis on behalf of the SIOP-E-HGG/DIPG working group.
    Eur J Cancer. 2017;73:38-47.
    PubMed     Abstract available

  75. FOSSARD G, Ferlay C, Nicolas-Virelizier E, Rey P, et al
    Utility of post-therapy brain surveillance imaging in the detection of primary central nervous system lymphoma relapse.
    Eur J Cancer. 2017;72:12-19.
    PubMed     Abstract available

  76. MANIAS KA, Gill SK, MacPherson L, Foster K, et al
    Magnetic resonance imaging based functional imaging in paediatric oncology.
    Eur J Cancer. 2017;72:251-265.
    PubMed     Abstract available

    January 2017
  77. URSU R, Carpentier A, Metellus P, Lubrano V, et al
    Intracerebral injection of CpG oligonucleotide for patients with de novo glioblastoma-A phase II multicentric, randomised study.
    Eur J Cancer. 2017;73:30-37.
    PubMed     Abstract available

  78. TUCHEN M, Wilisch-Neumann A, Daniel EA, Baldauf L, et al
    Receptor tyrosine kinase inhibition by regorafenib/sorafenib inhibits growth and invasion of meningioma cells.
    Eur J Cancer. 2017;73:9-21.
    PubMed     Abstract available

  79. KHATUA S, Ramaswamy V, Bouffet E
    Current therapy and the evolving molecular landscape of paediatric ependymoma.
    Eur J Cancer. 2017;70:34-41.
    PubMed     Abstract available

    December 2016
  80. GENRE L, Roche H, Varela L, Kanoun D, et al
    External validation of a published nomogram for prediction of brain metastasis in patients with extra-cerebral metastatic breast cancer and risk regression analysis.
    Eur J Cancer. 2016;72:200-209.
    PubMed     Abstract available

    November 2016
  81. OULDAMER L, Bendifallah S, Chas M, Boivin L, et al
    Intrinsic and extrinsic flaws of the nomogram predicting bone-only metastasis in women with early breast cancer: An external validation study.
    Eur J Cancer. 2016;69:102-109.
    PubMed     Abstract available

Thank you for your interest in scientific medicine.

AMEDEO Neoplasms of the CNS is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.